However, HCC-1.2 and HCC-3 cell lines established in Austria exhibited higher levels of erlotinib metabolizing enzymes CYP1A2 and CYP3A4 as compared to commercially available Huh7 and SNU398. The gene discussed is CYP1A2; the disease is hepatocellular carcinoma.